First design
Site theme
Sign up or sign in to sign up for discussions!
Pfizer’s executive leader has thwarted any persistent hope that knowledge of the COVID-19 vaccine will be noticed before next week’s election.
The pharmaceutical giant has the fastest clinical trial design among the pioneers of the COVID-19 vaccine race. And for weeks, Pfizer CEO Albert Bourla has hinted at the option of his company gaining effect until the end of October, a seductive perspective assumed through President Donald Trump, who has been pushing for vaccine news in October for his re-election candidacy.
“Let’s be very patient,” he said in the call, according to the New York Times. “I know how much the degrees of tension are increasing. I know how much the vaccine is in the world. “
He also tried to ease political tension over the vaccine’s results, saying, “It may not be a Republican vaccine or a Democratic vaccine. It will be a vaccine for the citizens of the world. I hope it’s effective. “
As the Times noted, Pfizer’s test design is one of the fastest among the few trials of maximum complexity, adding trials conducted through Moderna, AstraZeneca and Johnson.
The interim investigation of 32 Instances of Pfizer is the first of 4 planned for the trial, which is expected to last until 164 instances occur. For the first 32-instance research, researchers will be positive about vaccine customers if 26 or more of those instances involve others who have won only one placebo.
But for now, the 32-instance threshold for provoking an intermediate analysis does not appear to have been met, Bourla warned in today’s appeal. This is good news and bad news, as STAT has pointed out. it has obviously not yet failed, but it also suggests that the trial is progressing more slowly than expected, has several foreign control sites, adding the United States, Argentina, Brazil, South Africa, Germany and Turkey.
Join Ars Orbital Transmission mail for weekly updates to your inbox.